CO2021003947A2 - Células productoras de insulina - Google Patents

Células productoras de insulina

Info

Publication number
CO2021003947A2
CO2021003947A2 CONC2021/0003947A CO2021003947A CO2021003947A2 CO 2021003947 A2 CO2021003947 A2 CO 2021003947A2 CO 2021003947 A CO2021003947 A CO 2021003947A CO 2021003947 A2 CO2021003947 A2 CO 2021003947A2
Authority
CO
Colombia
Prior art keywords
insulin
cells
producing cells
positive
proportion
Prior art date
Application number
CONC2021/0003947A
Other languages
English (en)
Spanish (es)
Inventor
Ryo Ito
Noriko Yamazoe
Hideyuki HIYOSHI
Taisuke Mochida
Hikaru Ueno
Kensuke Sakuma
Junji Yamaura
Hirokazu Matsumoto
Taro Toyoda
Shuhei Konagaya
Original Assignee
Takeda Pharmaceuticals Co
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Univ Kyoto filed Critical Takeda Pharmaceuticals Co
Publication of CO2021003947A2 publication Critical patent/CO2021003947A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2021/0003947A 2018-09-19 2021-03-29 Células productoras de insulina CO2021003947A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018175465 2018-09-19
PCT/JP2019/037725 WO2020059892A1 (ja) 2018-09-19 2019-09-18 インスリン産生細胞

Publications (1)

Publication Number Publication Date
CO2021003947A2 true CO2021003947A2 (es) 2021-04-19

Family

ID=69887298

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003947A CO2021003947A2 (es) 2018-09-19 2021-03-29 Células productoras de insulina

Country Status (14)

Country Link
US (1) US20210353686A1 (cg-RX-API-DMAC7.html)
EP (1) EP3854869A4 (cg-RX-API-DMAC7.html)
JP (1) JP7295576B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892433B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867787B (cg-RX-API-DMAC7.html)
AU (1) AU2019343003B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004815A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003947A2 (cg-RX-API-DMAC7.html)
IL (1) IL281531B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003147A (cg-RX-API-DMAC7.html)
SG (1) SG11202102748WA (cg-RX-API-DMAC7.html)
TW (1) TWI862513B (cg-RX-API-DMAC7.html)
WO (1) WO2020059892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
CN116391028A (zh) * 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
TW202246489A (zh) * 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
JP2024542041A (ja) 2021-11-01 2024-11-13 バーテックス ファーマシューティカルズ インコーポレイテッド 幹細胞由来の膵臓島分化
IL315122A (en) * 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
EP4596675A4 (en) 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS
EP4753734A1 (en) * 2023-08-02 2026-06-10 Joslin Diabetes Center, Inc. Ribosomal remodeling in diabetes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005096873A1 (de) 2004-04-10 2005-10-20 Henkel Kommanditgesellschaft Auf Aktien Lockenwickler
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
NZ571427A (en) * 2006-03-02 2012-07-27 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
JP2010528622A (ja) 2007-05-30 2010-08-26 ザ ジェネラル ホスピタル コーポレイション 体細胞から多能性細胞を生成する方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009012428A2 (en) 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
JP5875597B2 (ja) * 2010-12-08 2016-03-02 ヴィアサイト,インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
US20120270890A1 (en) * 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
RU2705001C2 (ru) * 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
IL321825A (en) * 2013-02-06 2025-08-01 Viacyte Inc Cell compositions derived from dedifferentiated reprogrammed cells
WO2015002888A1 (en) * 2013-07-01 2015-01-08 Trustees Of Boston University Dissolvable hydrogel compositions for wound management and methods of use
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
CN107250349A (zh) * 2014-12-19 2017-10-13 詹森生物科技公司 多能干细胞的悬浮培养
HK1254740A1 (zh) * 2015-11-30 2019-07-26 Kadimastem Ltd. 分化和纯化胰腺内分泌细胞的方法
MA45329A (fr) * 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
JP6863805B2 (ja) 2017-04-14 2021-04-21 グローリー株式会社 各台装置及び各台装置制御方法
AU2019261083B2 (en) * 2018-04-23 2025-01-23 Orizuru Therapeutics, Inc. Growth inhibitor

Also Published As

Publication number Publication date
AU2019343003A1 (en) 2021-05-13
CN112867787B (zh) 2024-11-22
IL281531B1 (en) 2024-11-01
KR20210060446A (ko) 2021-05-26
BR112021004815A2 (pt) 2021-06-01
IL281531A (en) 2021-05-31
TW202026420A (zh) 2020-07-16
MX2021003147A (es) 2021-05-14
WO2020059892A1 (ja) 2020-03-26
IL281531B2 (en) 2025-03-01
SG11202102748WA (en) 2021-04-29
CA3113608A1 (en) 2020-03-26
EP3854869A4 (en) 2022-09-07
CN112867787A (zh) 2021-05-28
TWI862513B (zh) 2024-11-21
JP7295576B2 (ja) 2023-06-21
US20210353686A1 (en) 2021-11-18
JPWO2020059892A1 (ja) 2021-08-30
KR102892433B1 (ko) 2025-11-27
EP3854869A1 (en) 2021-07-28
AU2019343003B2 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
AR081040A1 (es) Diferenciacion de celulas madre embrionarias humanas
CO2021001064A2 (es) Método para la producción de las células t gamma delta
AR082820A1 (es) Diferenciacion de celulas madre embrionarias humanas
CL2025001987A1 (es) Método para producir una planta modificada.
AR094348A1 (es) Diferenciación de células madre embrionarias humanas a células pancreáticas endocrinas con el uso de reguladores hb9
BR112017004046A2 (pt) processo de produção de butadieno e hidrogênio, a partir de etanol em duas etapas reacionais de baixo consumo em água e em energia
AR077767A1 (es) Diferenciacion de celulas madre embrionarias humanas
AR094347A1 (es) Cultivo de células madre embrionarias humanas en la interfase aire-líquido para la diferenciación en células endocrinas pancreáticas
PE20181138A1 (es) Metodo para producir l-aminoacidos
AR090970A1 (es) Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico
PE20210105A1 (es) Microorganismo del genero corynebacterium que produce l-aminoacidos y metodo para producir l-aminoacidos usando el mismo
CL2016001883A1 (es) Método para obtener cepas de levadura con producción de etanol baja, cepas de levadura obtenidas a partir de estas y su uso
MX2019002154A (es) Metodo de regulacion de caracteristica de planta.
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
CL2017000754A1 (es) Proceso para producir una biomasa que contiene pufa que tiene alta estabilidad celular
MX2021003147A (es) Celulas productoras de insulina.
CL2017001632A1 (es) Manufactura de proteína.
AR065634A1 (es) Metodo para la produccion de acido citrico
CO2021002704A2 (es) Método de producción de precursores neuronales entéricos
CL2022000470A1 (es) Método para disminuir el contenido de glicoformas ricas en manosa de una proteína recombinante (divisional de la solicitud de patente no. 201601786)
SG10201806655TA (en) Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same
PH12021550347A1 (en) MICROORGANISM FOR PRODUCING L-AMINO ACID WITH ENHANCED ACTIVITY OF a-GLUCOSIDASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME
PE20161484A1 (es) Composiciones de siloxano y metodos para reducir los cov y el polvo de siloxano
BR112016005456A2 (pt) método para produzir um l-aminoácido por um método de fermentação, e, dna isolado
CO2021008763A2 (es) Enzima de desfosforilación del nuevo ácido psicosa-6-fosfórico, composición para producir psicosa que comprende la misma y método para preparar psicosa usando la misma